Skip to main content

Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

 

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.99
+1.56 (0.68%)
AAPL  271.18
+0.21 (0.08%)
AMD  214.29
-0.66 (-0.31%)
BAC  56.06
+0.18 (0.32%)
GOOG  314.28
+2.95 (0.95%)
META  662.64
+1.14 (0.17%)
MSFT  485.98
+1.06 (0.22%)
NVDA  185.22
+1.53 (0.83%)
ORCL  194.19
-4.19 (-2.11%)
TSLA  487.08
-1.65 (-0.34%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.